Ensysce Biosciences
ENSC
12 hedge funds and large institutions have $581K invested in Ensysce Biosciences in 2024 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 4 closing their positions.
129% more capital invested
Capital invested by funds: $253K → $581K (+$327K)
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
9% more funds holding
Funds holding: 11 → 12 (+1)
0.99% more ownership
Funds ownership: 0.44% → 1.43% (+0.99%)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$398K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$343K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$45.6K |
| 4 |
HF
HRT Financial
New York
|
+$9.53K |
| 5 |
Renaissance Technologies
New York
|
+$9.06K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$25.4K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$6.7K |
| 3 |
VF
Virtu Financial
New York
|
-$6K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$728 |
| 5 |
MSG
Main Street Group
Glen Allen,
Virginia
|
-$185 |
ENSC Hedge Fund Activity: Q3 2024 in Review
12 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Ensysce Biosciences (ENSC) for Q3 2024, worth a combined $581K — up 129% from $253K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ENSC positions and 4 closed out — a net gain of 1 holder — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $398K. The largest seller was Citadel Advisors, cutting an estimated $25.4K.
- 12 institutional investors held Ensysce Biosciences (ENSC) as of Q3 2024, up from 11 in Q2 2024.
- Funds reported $581K of Ensysce Biosciences stock for Q3 2024, up 129% quarter-over-quarter.
- 5 funds opened new Ensysce Biosciences positions in Q3 2024 and 4 closed out, a net change of +1 holder.
- The largest Ensysce Biosciences buyer in Q3 2024 was Anson Funds Management, an estimated $398K added.
- The largest Ensysce Biosciences seller in Q3 2024 was Citadel Advisors, an estimated $25.4K sold.
Based on aggregated 13F filings for Q3 2024.